Metabolon’s Revolutionary Metabolomic Platform and Services Proven in Over 3,000 Published Studies Across Diverse Fields!

Metabolon, Inc., the world-renowned leader in metabolomics solutions for research, diagnostics, therapy development, and precision medicine, is proud to announce that its metabolomics platform and services have been cited in over 3,000 peer-reviewed journals!

For two decades, the company has been refining its platform to unlock the full potential of metabolomics across all areas of life sciences research. Through the application of their high-quality metabolomic outputs, Metabolon has achieved this remarkable milestone.

Metabolon’s contributions to the life sciences and scientific innovation communities have been widely recognized, evidenced by the 1,000th peer-reviewed article citing its results in 2016. Since then, the number of publications citing Metabolon has rapidly increased, with nearly 75 in January and February 2023 alone.

These articles have been published in prestigious journals such as Nature, Nature Medicine, Nature Genetics, Cell, and Proceedings of the National Academy of Sciences (PNAS), demonstrating the importance of metabolomics in research.

Metabolon continues to support active collaboration across scientific disciplines and is driving continuous growth and adoption of its platform and results. With over 3,000 publications citing its contributions, Metabolon’s impact on the scientific community is undeniable.

Metabolon’s contributions to scientific research have been featured in some of the world’s most prestigious and high-impact journals, such as Nature, Nature Medicine, Nature Genetics, Cell, and Proceedings of the National Academy of Sciences (PNAS).

Recognized for its groundbreaking work, Metabolon proudly celebrated its 1,000th peer-reviewed article in 2016 and has since seen a dramatic increase in citations. With nearly 75 publications cited in January and February 2023 alone, there are now over 3,000 articles citing Metabolon’s research, covering topics ranging from COVID-19 to inflammation.

As a leader in the life sciences and scientific innovation communities, Metabolon continues to drive scientific progress and collaboration across disciplines.

At Metabolon, we are passionate about advancing the use of metabolomics to unlock the mysteries of human health and wellness. Our goal is to bridge the gap between basic science, clinical research, and medicine to bring about revolutionary changes in drug development.

We are actively engaging with the scientific community to promote the importance of metabolomics and its ability to provide a functional and phenotypic link between discovery and clinical development that is unmatched by gene-based applications. Together, we can make a real difference in the future of healthcare.

Metabolon’s metabolomics platform and services have been cited across a wide range of scientific disciplines, demonstrating the growing impact of metabolomics in these fields of research.

As Chief Scientific Officer Ranga Sarangarajan noted, this milestone is a testament to Metabolon’s commitment to providing top-notch metabolomics outputs and advancing tools and capabilities for sophisticated statistical analysis, multi-omics data integration, and machine learning and artificial intelligence analytics.

Metabolon is helping to transform the way scientists approach and incorporate metabolomics into life science, health, and wellness research.

For two decades, Metabolon has been the leading provider of metabolomics data and services. Our team of over 45 PhDs combined with our expansive reference library of over 5,400 metabolites has enabled us to complete over 10,000 projects in a variety of industries, including biopharma, population health, consumer products, agriculture, wellness, and academic and government research.

With such a vast array of expertise and data, Metabolon is your go-to provider for reliable metabolomics data and services.

About Metabolon

Metabolon, Inc. is revolutionizing the world of life sciences research by providing groundbreaking biochemical data and insights. For over 20 years, Metabolon has been the global leader in metabolomics, with over 10,000 projects, 3,000 publications, and certifications from both ISO 9001:2015 and CLIA.

Not only is the company equipped with the world’s largest proprietary metabolomics reference library, but they also offer customers and partners transformative metabolomics and lipidomics solutions from discovery to clinical trials and beyond. With Metabolon’s pioneering technology and knowledge, life sciences research has never been easier or more successful.

About Metabolomics

Metabolomics is the only ‘omics technology that provides an all-encompassing view of a biological system. By measuring thousands of discrete chemical signals, it can provide insight into the complex interplay between genetics, drugs, diet, lifestyle and the microbiome on human health.

Metabolomics is invaluable for uncovering biomarkers, enabling researchers to understand a drug’s mechanism of action, pharmacodynamics and safety profile, as well as individual responses to therapy. This comprehensive approach to understanding biological systems gives us an unprecedented window into the future of human health.

Leave a Comment